CTLA4 and cancer: BRAF inhibitors and anti-CTLA-4 and anti-PD-1 monoclonal antibodies are changing the landscape of cancer treatments (Eagle and Trowsdale, 2007; Chapman et al., 2011; Mellman et al., 2011; Wolchok et al., 2013; Hamid et al., 2013).